Teleflex (TFX) said four-year follow-up data from its BIOMAG-I study continued to show a favorable long-term safety profile for its Freesolve resorbable magnesium scaffold, the company said Tuesday.
The study of 116 patients across Europe reported no cardiac death, target-vessel MI, or scaffold thrombosis through four years, with a 3.5% target lesion failure rate, the company added.
Teleflex said the findings support ongoing trials and strengthen the case for the resorbable scaffold as an alternative to drug-eluting stents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments